Hisamitsu Pharmaceutical Co., Inc. (4530) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hisamitsu Pharmaceutical Co., Inc. (4530:JPX), powered by AI.

Current Price
¥6,040
P/E Ratio
20.4
Market Cap
444.6B
Sector
Healthcare
What is the Hisamitsu Pharmaceutical Co., Inc. stock price forecast?

Hisamitsu Pharmaceutical Co., Inc. is currently trading at ¥6,040. View real-time AI analysis on Alpha Lenz.

What is Hisamitsu Pharmaceutical Co., Inc. insider trading activity?

View the latest insider trading data for Hisamitsu Pharmaceutical Co., Inc. on Alpha Lenz.

What is Hisamitsu Pharmaceutical Co., Inc.'s P/E ratio?

Hisamitsu Pharmaceutical Co., Inc.'s P/E ratio is 20.4.

Hisamitsu Pharmaceutical Co., Inc.

JPX · 4530
¥6,040+0(+0.00%)Market closedJPX regular session 09:00–15:00 JST
Ask about Hisamitsu Pharmaceutical Co., Inc.'s future dividend policy...
Alpha Chat Insight

Hisamitsu Pharmaceutical Co., Inc. trades at a P/E of 20.4 (fair value) with solid ROE of 8.0%.

Ask for details

Company Overview

Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company known for developing and producing over-the-counter medicines and therapeutic products, with a focus on topical treatments. Established in Japan, the company's primary purpose is to enhance quality of life by providing pain relief and therapeutic solutions, particularly through innovative transdermal delivery systems. They are renowned for their pioneering work in patches, such as Salonpas, which offer a non-invasive method for delivering medication directly through the skin. Hisamitsu's products are widely used across various sectors including healthcare environments, individual consumers, and sports medicine. The company has a significant impact on both local and global markets, contributing to advancements in pain management and healthcare technology. Hisamitsu's focus on research and development keeps it at the forefront of pharmaceutical innovation, maintaining its reputation as a leader in therapeutic skin care solutions.

CEOMr. Kazuhide Nakatomi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees2,799

Company Statistics

FY 2025

Profile

¥444,626,723,840Market Cap
¥156,006,000,000Revenue
0.00Shares Out
2,799Employees

Margins

58.46%Gross
19.47%EBITDA
12.11%Operating
18.39%Pre-Tax
14.29%Net

Valuation

20.44P/E
1.61P/B
2.85EV/Sales
11.08EV/EBITDA
89.09P/FCF

Growth (CAGR)

9.08%Rev 3Yr
2.04%Rev 5Yr
26.49%Op Inc 3Yr
-3.63%Op Inc 5Yr
31.26%Net Inc 3Yr
3.35%Net Inc 5Yr

Returns

6.64%ROA
8.03%ROE
8.55%ROIC

Financial Health

¥114,518,000,000Cash & Cash Equivalents
¥-50,853,000,000Net Debt
22.79%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Hisamitsu Pharmaceutical Co., Inc. (ticker: 4530) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,799 employees. Market cap is $444.6B.

The current price is 6,040 with a P/E ratio of 20.44x and P/B of 1.61x.

ROE is 8.03% and operating margin is 12.11%. Annual revenue is $156.0B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Hisamitsu Pharmaceutical Co., Inc. (4530) Stock Forecast 2026 ¥6,040 — Price, Financials & Analyst Targets | Alpha Lenz